Maxillomandibular advancement for the treatment of obstructive sleep apnoea syndrome: a long-term follow-up

Maxillomandibular advancement for the treatment of obstructive sleep apnoea syndrome: a long-term follow-up: Obstructive sleep apnoea syndrome (OSAS), which is characterised by repetitive episodes of pharyngeal collapse during sleep, is gaining much attention because of the important deleterious consequences it might have on the patient’s health. We therefore organised a retrospective longitudinal study to report the long-term follow-up of maxillomandibular advancement (MMA) as a treatment for OSAS. A total of 19 patients with severe OSAS was treated during the period 2007–2016. They were followed up six months postoperatively (T1) and after a mean follow up of 6.7 (range 4-10) years (T2, between November 2017 and February 2018) for the polysomnography variables, and the Epworth sleeping scale (ESS) and body mass index (BMI) were recorded.